On Monday, Cognition Therapeutics Inc (NASDAQ: CGTX) opened higher 8.57% from the last session, before settling in for the closing price of $0.30. Price fluctuations for CGTX have ranged from $0.28 to $2.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 50.00% at the time writing. With a float of $50.25 million, this company’s outstanding shares have now reached $61.97 million.
Let’s determine the extent of company efficiency that accounts for 28 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cognition Therapeutics Inc (CGTX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cognition Therapeutics Inc is 18.94%, while institutional ownership is 8.59%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 50.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.61% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Check out the current performance indicators for Cognition Therapeutics Inc (CGTX). In the past quarter, the stock posted a quick ratio of 2.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Looking closely at Cognition Therapeutics Inc (NASDAQ: CGTX), its last 5-days average volume was 2.51 million, which is a jump from its year-to-date volume of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 14.24%. Additionally, its Average True Range was 0.04.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 4.64%, which indicates a significant decrease from 24.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 114.75% in the past 14 days, which was higher than the 97.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4040, while its 200-day Moving Average is $0.5603. However, in the short run, Cognition Therapeutics Inc’s stock first resistance to watch stands at $0.3419. Second resistance stands at $0.3570. The third major resistance level sits at $0.3740. If the price goes on to break the first support level at $0.3098, it is likely to go to the next support level at $0.2928. Should the price break the second support level, the third support level stands at $0.2777.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
There are currently 61,975K shares outstanding in the company with a market cap of 20.26 million. Presently, the company’s annual sales total 0 K according to its annual income of -33,970 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -7,840 K.
